Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo.

The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...

The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.

Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...

In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) cleared Opdivo (nivolumab) for use with platinum-based chemo to reduce the size ...

Bristol Myers Squibb has received FDA approval for Opdivo (nivolumab) combined with chemotherapy as a perioperative treatment ...

BriaCell Therapeutics announced that its Bria-IMT cell therapy, plus an immune checkpoint inhibitor regimen, achieved ...

Today, FMI President and CEO Leslie Sarasin issued the following statement: "Shoppers may be worried about their grocery needs due to the ongoing strike by the International Longshoremen's Association ...

Illumina, Inc. , a global leader in DNA sequencing and array-based technologies, announced that after 11 years of service, Charles "Chuck" Dadswell will step down as General Counsel and Secretary on ...

The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with ...

The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.

The Food and Drug Administration has approved Opdivo before and after surgery for some with non-small cell lung cancer.